Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 260

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Open access
Deek, Matthew P., Van der Eecken, Kim, Sutera, Philip, Deek, Rebecca A., Fonteyne, Valérie, Mendes, Adrianna A., Decaestecker, Karel, Kiess, Ana Ponce, Lumen, Nicolaas, Phillips, Ryan, De Bruycker, Aurélie, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Lambert, Bieke, Delrue, Louke, Wang, Hailun, Lowe, Kathryn, Verbeke, Sofie, Van Dorpe, Jo, Bultijnck, Renée, Villeirs, Geert, De Man, Kathia, Ameye, Filip, Song, Daniel Y., DeWeese, Theodore, Paller, Channing J., Feng, Felix Y., Wyatt, Alexander, Pienta, Kenneth J., Diehn, Maximillian, Bentzen, Soren M., Joniau, Steven, Vanhaverbeke, Friedl, De Meerleer, Gert, Antonarakis, Emmanuel S., Lotan, Tamara L., Berlin, Alejandro, Siva, Shankar, Ost, Piet, Tran, Phuoc T. · 2022 · Journal of Clinical Oncology

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.22.00644

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 260

Metadata

Authors
Deek, M. P., Van der Eecken, K., Sutera, P., Deek, R. A., Fonteyne, V., Mendes, A. A., Decaestecker, K., Kiess, A. P., Lumen, N., Phillips, R., De Bruycker, A., Mishra, M., Rana, Z., Molitoris, J., Lambert, B., Delrue, L., Wang, H., Lowe, K., Verbeke, S., Van Dorpe, J., Bultijnck, R., Villeirs, G., De Man, K., Ameye, F., Song, D. Y., DeWeese, T., Paller, C. J., Feng, F. Y., Wyatt, A., Pienta, K. J., Diehn, M., Bentzen, S. M., Joniau, S., Vanhaverbeke, F., De Meerleer, G., Antonarakis, E. S., Lotan, T. L., Berlin, A., Siva, S., Ost, P., & Tran, P. T.
Venue
Journal of Clinical Oncology
Published
2022-10-10
Volume
40
Issue
29
Pages
3377-3382
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4292978844
Cited by
260
References
15
FWCI
29.46
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.